Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

rter culminated with the FDA approval of DIFICID for the treatment of C. difficile-associated diarrhea, or CDAD, in patients over the age of 18, which includes clear differentiation and superiority over oral vancomycin in sustained clinical response 25 days after the end of therapy," said Pedro Lichtinger, President and CEO of Optimer.  "Our success with the FDA approval and the recent launch of DIFICID can be attributed to thorough preparation and execution by our team. We remain highly focused on the successful introduction of DIFICID to physicians and patients, and on establishing DIFICID, based on the clinical experience to date, as the preferred treatment for CDAD patients."

Second Quarter and Recent Highlights

  • On May 27, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID™ (fidaxomicin) Tablets for the treatment of CDAD in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease.
  • On July 18, Optimer announced the commercial launch of DIFICID™ Tablets for the treatment of CDAD in patients 18 years of age and older.
  • Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDAD in the U.S. to help maximize the impact of, and de-risk, the commercial launch of DIFICID.
  • Optimer also presented additional data analysis from the DIFICID Phase 3 clinical trials highlighting risk factors associated with negative outcomes in patients with CDAD such as advanced age and immunosuppression. Data were presented at key scientific conferences including the European Congress of Clinical Microbiology and Infectious Diseases, Digestive Disease Week and the Annual Meeting of the American Geriatric Society.

  • About Op
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
    2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
    5. Optimer Pharmaceuticals Expands Senior Management Team
    6. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
    7. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
    8. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
    9. Trading Halted Today in Optimer Pharmaceuticals Stock
    10. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
    (Date:9/2/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ... study.  Results of the study presented by a ... cardiology congress and concurrently published by the ... Therapy (ART) in patients with moderate to severe ... safe, improves the heart,s ability to pump blood, ...
    (Date:9/2/2014)... , Sept. 2, 2014 ResMed (NYSE: ... 150 devices in the United States ... portable, lightweight, and user-friendly life support ventilators. ... mobility and ease of use for patients suffering from ... adult and childhood respiratory disorders. The U.S. launch comes ...
    Breaking Medicine Technology:EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3
    ... Formation in ... Animals, Hearts, SUNRISE, ... of myoblasts modified to express,stromal derived factor-1(alpha) protein (SDF-1) into the ... were recently,presented at two scientific meetings -- the International Society for,Magnetic ...
    ... Enrollment Program Speeds Oncology Patient Accrual, ... Research Management,Organization (RMO), has contracted with five ... management services for their,clinical trials using the ... the following disease indications: follicular Non-Hodgkin,s,Lymphoma, Metastatic ...
    Cached Medicine Technology:Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2
    (Date:9/2/2014)... Boca Raton, FL (PRWEB) September 02, 2014 ... online audience targeting and multi-channel email marketing is pleased ... to the market, Firearms & Freedom as ... these online properties represent more than one million concerned ... and display advertising. , “We are honored to ...
    (Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
    (Date:9/2/2014)... of California, San Diego School of Medicine have identified ... The findings, reported in the current issue of ... cancer mortality worldwide. An estimated 40,000 women in America ... the American Cancer Society. , "The take-home message of ... to target breast cancer metastasis through a pathway regulated ...
    (Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
    (Date:9/2/2014)... 02, 2014 To commemorate the 13th ... children’s literacy organization that has donated more than 200,000 ... founding in 2001, will host the 5th Annual BJF ... p.m. at Barnes & Noble Tribeca. Featuring special guest ... public event for children and families will celebrate the ...
    Breaking Medicine News(10 mins):Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Brooke Jackman Foundation Hosts 5th Annual Read-A-Thon, A Celebration of Hope and Literacy in New York City to Commemorate 13th Anniversary of 9/11 2Health News:Brooke Jackman Foundation Hosts 5th Annual Read-A-Thon, A Celebration of Hope and Literacy in New York City to Commemorate 13th Anniversary of 9/11 3
    ... , TUESDAY, Sept. 27 (HealthDay News) -- Men may need ... suggests. The study found that men were far more ... adenomas) in their colon -- 24.9 percent of men compared ... at an earlier age. "In our study, analysis of ...
    ... Discussing and documenting patients, preferences for care at the end ... recent claims. A new study published today in the ... with their physicians about end-of-life care and have an advance ... patients who do not have these discussions and documents. ...
    ... Steven Reinberg HealthDay Reporter , TUESDAY, Sept. 27 ... to an enlarged prostate, saw palmetto extract doesn,t seem to ... at high doses, a new study finds. Many men ... relieve lower urinary tract symptoms related to benign prostatic hyperplasia ...
    ... been honored with the Presidential Early Career Award ... and scientific leadership. It is the highest honor ... engineering professionals in the early stages of their ... Sept. 26. Justin Kasper, an astrophysicist at ...
    ... TUESDAY, Sept. 27 (HealthDay News) -- Average annual premiums for ... past year, to more than $15,000, according to new research ... Educational Trust. On average, U.S. workers now pay more ... has far outpaced growth in workers, wages, the 2011 employer ...
    ... an associate professor in the department of mathematical ... Arts, has received the honor of "Excellence in ... Convocation at NJIT traditionally honors select faculty ... level of excellence over a sustained period. ...
    Cached Medicine News:Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3Health News:Saw Palmetto Doesn't Help Enlarged Prostate: Study 2Health News:Saw Palmetto Doesn't Help Enlarged Prostate: Study 3Health News:President Barack Obama recognizes outstanding scientists at the Smithsonian 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 3Health News:Gifted mathematician honored at NJIT convocation 2
    ... DXC-990 camera is a 3 chip 1/2 inch color ... and a high s/n ratio. It offers picture contrast ... and knee control. The user can choose automatic exposure ... The Sony DXC-990 camera is a bayonet mount and ...
    Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
    ... image management. Mediscan is an advanced ... derived from extensive experience with clinicians. ... organize, and distribute high quality images, ... effort. Can be connected to flexible ...
    For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
    Medicine Products: